Concepedia

David W. Kang

DW

16

Publications

525

Citations

12

H-Index

2004

Active since

Affiliations

Halozyme Therapeutics (United States)(Current)

Monash University

SUNY Upstate Medical University

David W. Kang is an author at Halozyme Therapeutics (United States) specializing in medicine, matrix biology, and extracellular matrix.

ORCID

Top concepts

Publications per year

2004–2024

16

Publications

16

A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder.

Robert J. Gregory, Susan Chlebowski, David W. Kang et al. · Psychotherapy · 2008 · 144 citations

, , +19

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Lavinia Morosi, Marina Meroni, Paolo Ubezio et al. · Journal of Experimental & Clinical Cancer Research · 2021 · 52 citations · Full text

Synthetic Biocompatible Cyclodextrin-Based Constructs for Local Gene Delivery to Improve Cutaneous Wound Healing

Nathalie C. Bellocq, David W. Kang, Xuehui Wang et al. · Bioconjugate Chemistry · 2004 · 46 citations

, , +21

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

Stephen P Knowles, Marie A. Printz, David W. Kang et al. · Expert Opinion on Drug Delivery · 2021 · 39 citations · Full text

Single-Molecule Unbinding Forces between the Polysaccharide Hyaluronan and Its Binding Proteins

Fouzia Bano, Markku Tammi, David W. Kang et al. · Biophysical Journal · 2018 · 34 citations · Full text

Rows per page

1–5 of 16